Study of Patritumab Deruxtecan in Participants With Gastrointestinal Cancers (MK-1022-011) (HERTHENA-PanTumor02)
Merck Sharp & Dohme LLC
Merck Sharp & Dohme LLC
Revolution Medicines, Inc.
Institut du Cancer de Montpellier - Val d'Aurelle
Verastem, Inc.
H. Lee Moffitt Cancer Center and Research Institute
Intima Bioscience, Inc.
DualityBio Inc.
Lumicell, Inc.
M.D. Anderson Cancer Center
UNC Lineberger Comprehensive Cancer Center
DualityBio Inc.
National Institutes of Health Clinical Center (CC)
GlaxoSmithKline
BicycleTx Limited
Revolution Medicines, Inc.
National Institutes of Health Clinical Center (CC)
National University Hospital, Singapore
Bolt Biotherapeutics, Inc.
Turning Point Therapeutics, Inc.
Marengo Therapeutics, Inc.
Hoffmann-La Roche
Thomas Jefferson University
Imugene Limited
Erasca, Inc.
Binhui Biopharmaceutical Co., Ltd.
Columbia University
University of Kansas Medical Center
NantBioScience, Inc.
University of California, San Diego
Theseus Pharmaceuticals
Academic and Community Cancer Research United
Kyowa Kirin Co., Ltd.
InnoPharmax Inc.
Revolution Medicines, Inc.
Eastern Cooperative Oncology Group
Yangzhou University
Institut Cancerologie de l'Ouest
University of Texas Southwestern Medical Center
Isofol Medical AB
Isofol Medical AB
University of Maryland, Baltimore
Repos Pharma
Radboud University Medical Center
Generic Devices Consulting, Inc.
Dana-Farber Cancer Institute
Peking University Cancer Hospital & Institute
University Hospital Tuebingen
FeRx